

**Appendix 9.** Discrimination of risk predicting models in subgroup of high-risk CHB patients

**Supplementary Table 9-1.** Discrimination of risk predicting models in cirrhosis patients at initiation of antiviral treatment

MODEL	Year 2.5 (n=415)	Year 3 (n=402)	Year 3.5 (n=390)	Year 4 (n=376)	Year 4.5 (n=368)	Year 5 (n=347)
Untreated models without the cirrhosis variable						
REACH-B	0.56 (0.44,0.66)	0.58 (0.47,0.69)	0.53 (0.42,0.64)	0.52 (0.39,0.64)	0.56 (0.44,0.68)	0.51 (0.35,0.67)
NGM1-HCC	0.59 (0.46,0.70)	0.59 (0.47,0.70)	0.54 (0.41,0.66)	0.51 (0.39,0.64)	0.57 (0.44,0.69)	0.52 (0.36,0.67)
NGM2-HCC	0.56 (0.43,0.69)	0.59 (0.47,0.70)	0.53 (0.36,0.70)	0.53 (0.41,0.65)	0.55 (0.42,0.67)	0.55 (0.37,0.72)
Untreated models with the cirrhosis variable						
GAG-HCC	0.64 (0.54,0.73)	0.60 (0.49,0.71)	0.63 (0.54,0.72)	0.60 (0.50,0.69)	0.56 (0.45,0.67)	0.65 (0.50,0.78)
Treated or mixed models without the cirrhosis variable						
mREACH-BI	0.61 (0.49,0.71)	0.60 (0.49,0.70)	0.53 (0.40,0.66)	0.52 (0.41,0.62)	0.51 (0.39,0.63)	0.51 (0.35,0.67)
mREACH-BII	0.63 (0.52,0.73)	0.61 (0.50,0.72)	0.55 (0.43,0.67)	0.53 (0.43,0.64)	0.53 (0.42,0.65)	0.52 (0.35,0.68)
LSM-HCC	0.65 (0.54,0.74)	0.59 (0.47,0.71)	0.52 (0.42,0.63)	0.56 (0.45,0.67)	0.53 (0.40,0.66)	0.53 (0.38,0.67)
SAGE-B	0.68 (0.57,0.77)	0.60 (0.46,0.72)	0.55 (0.43,0.66)	0.58 (0.46,0.69)	0.52 (0.38,0.65)	0.51 (0.33,0.68)
mPAGE-B	0.60 (0.50,0.69)	0.60 (0.48,0.71)	0.54 (0.44,0.64)	0.54 (0.43,0.65)	0.50 (0.37,0.63)	0.53 (0.35,0.69)
PAGE-B	0.60 (0.50,0.69)	0.60 (0.48,0.70)	0.55 (0.45,0.65)	0.55 (0.42,0.67)	0.56 (0.41,0.69)	0.54 (0.32,0.75)
aMAP	0.60 (0.49,0.70)	0.63 (0.51,0.74)	0.53 (0.42,0.64)	0.57 (0.45,0.67)	0.54 (0.40,0.67)	0.53 (0.34,0.71)
Treated or mixed models with the cirrhosis variable						
GAG-HCC	0.64 (0.54,0.73)	0.60 (0.49,0.71)	0.63 (0.54,0.72)	0.60 (0.50,0.69)	0.56 (0.45,0.67)	0.65 (0.50,0.78)
AASL-HCC	0.66 (0.56,0.75)	0.62 (0.50,0.73)	0.63 (0.54,0.71)	0.59 (0.49,0.69)	0.56 (0.44,0.67)	0.63 (0.47,0.76)
CAMD	0.64 (0.53,0.73)	0.60 (0.49,0.71)	0.62 (0.52,0.70)	0.57 (0.47,0.67)	0.54 (0.42,0.66)	0.62 (0.46,0.75)
REAL-B	0.66 (0.56,0.76)	0.62 (0.51,0.72)	0.63 (0.52,0.73)	0.63 (0.52,0.73)	0.57 (0.44,0.69)	0.66 (0.47,0.81)
CU-HCC	0.61 (0.51,0.71)	0.59 (0.47,0.70)	0.59 (0.50,0.68)	0.60 (0.48,0.71)	0.55 (0.42,0.66)	0.65 (0.49,0.78)
RWS-HCC	0.68 (0.57,0.78)	0.65 (0.54,0.75)	0.67 (0.57,0.75)	0.70 (0.61,0.77)	0.70 (0.57,0.80)	0.68 (0.51,0.82)
CAGE-B	0.65 (0.55,0.74)	0.59 (0.47,0.71)	0.54 (0.43,0.65)	0.55 (0.45,0.65)	0.53 (0.41,0.65)	0.53 (0.39,0.68)

**Supplementary Table 9-2.** Discrimination of risk predicting models in patients stratified as intermediate- or high-risk categories by corresponding models at baseline

MODEL	Year 2.5	Year 3	Year 3.5	Year 4	Year 4.5	Year 5
Untreated models with the cirrhosis variable						
GAG-HCC	0.60 (0.50,0.70)	0.58 (0.45,0.69)	0.59 (0.48,0.69)	0.54 (0.42,0.65)	0.51 (0.37,0.64)	0.70 (0.56,0.81)
Treated models without the cirrhosis variable						
LSM-HCC	0.68 (0.58,0.78)	0.64 (0.52,0.75)	0.60 (0.49,0.70)	0.65 (0.53,0.75)	0.62 (0.50,0.74)	0.55 (0.38,0.71)
SAGE-B	0.69 (0.59,0.78)	0.60 (0.44,0.74)	0.60 (0.47,0.71)	0.60 (0.47,0.71)	0.52 (0.38,0.66)	0.51 (0.35,0.67)
mPAGE-B	0.60 (0.50,0.69)	0.60 (0.48,0.71)	0.56 (0.46,0.66)	0.55 (0.43,0.66)	0.52 (0.38,0.65)	0.51 (0.34,0.67)
PAGE-B	0.63 (0.53,0.72)	0.63 (0.52,0.72)	0.63 (0.52,0.72)	0.59 (0.46,0.72)	0.59 (0.44,0.72)	0.58 (0.41,0.74)
aMAP	0.66 (0.57,0.75)	0.67 (0.57,0.77)	0.62 (0.52,0.71)	0.63 (0.52,0.73)	0.60 (0.48,0.71)	0.58 (0.40,0.74)
Treated models with the cirrhosis variable						
AASL-HCC	0.67 (0.57,0.75)	0.63 (0.52,0.73)	0.65 (0.55,0.73)	0.63 (0.53,0.72)	0.57 (0.45,0.68)	0.61 (0.45,0.75)
CAMD	0.64 (0.54,0.74)	0.60 (0.49,0.71)	0.63 (0.54,0.71)	0.58 (0.48,0.68)	0.53 (0.41,0.65)	0.60 (0.45,0.73)
REAL-B	0.69 (0.59,0.77)	0.64 (0.53,0.74)	0.65 (0.54,0.74)	0.65 (0.54,0.74)	0.56 (0.44,0.67)	0.65 (0.48,0.78)
CU-HCC	0.65 (0.55,0.74)	0.63 (0.51,0.73)	0.64 (0.55,0.72)	0.64 (0.53,0.74)	0.58 (0.47,0.69)	0.67 (0.52,0.79)
RWS-HCC	0.67 (0.56,0.77)	0.65 (0.54,0.75)	0.68 (0.58,0.76)	0.70 (0.62,0.77)	0.71 (0.59,0.80)	0.69 (0.52,0.83)
CAGE-B	0.69 (0.59,0.77)	0.63 (0.50,0.75)	0.59 (0.48,0.70)	0.60 (0.50,0.70)	0.50 (0.37,0.62)	0.54 (0.39,0.69)

Notes: Subgroup analysis by baseline risk categories were not performed for REACH-B, NGM1-HCC, NGM2-HCC, mREACH-BI, mREACH-BII, since no cutoff to classify patients according to HCC risk were reported in original developing studies.